Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic atrophy (GA), a major cause of irreversible sight loss that affects ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching ...

Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.

In the month of March, not only did trials progress, but approvals for new and expanded uses of treatments were issued.